CN106256835A - High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes - Google Patents
High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes Download PDFInfo
- Publication number
- CN106256835A CN106256835A CN201610694877.4A CN201610694877A CN106256835A CN 106256835 A CN106256835 A CN 106256835A CN 201610694877 A CN201610694877 A CN 201610694877A CN 106256835 A CN106256835 A CN 106256835A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- human
- ctp
- hgh
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 119
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 119
- 108010000521 Human Growth Hormone Proteins 0.000 title claims abstract description 71
- 102000002265 Human Growth Hormone Human genes 0.000 title claims abstract description 71
- 239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 71
- 238000006206 glycosylation reaction Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 30
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 15
- 229940088597 hormone Drugs 0.000 claims abstract description 14
- 239000005556 hormone Substances 0.000 claims abstract description 14
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 12
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 12
- 210000001136 chorion Anatomy 0.000 claims abstract description 8
- 230000001456 gonadotroph Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000013595 glycosylation Effects 0.000 claims description 15
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 9
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102220315697 rs1553622313 Human genes 0.000 claims description 6
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 102000018997 Growth Hormone Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960004532 somatropin Drugs 0.000 claims description 3
- 210000003771 C cell Anatomy 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- -1 linker aminoacid Chemical class 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 102200072304 rs1057519530 Human genes 0.000 claims description 2
- 102200124454 rs80356507 Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 15
- 230000000857 drug effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 4
- 102000018358 immunoglobulin Human genes 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 30
- 101100492752 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-3 gene Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 25
- 230000004927 fusion Effects 0.000 description 18
- 102100028829 Heat shock 70 kDa protein 4L Human genes 0.000 description 17
- 101001078634 Homo sapiens Heat shock 70 kDa protein 4L Proteins 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 9
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 101710128947 Tricarboxylate transport protein, mitochondrial Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108700018610 polyethylene glycol-recombinant human growth hormone Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000003335 steric effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100164201 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-4 gene Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000003147 glycosyl group Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100032559 Clathrin light chain B Human genes 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000942271 Homo sapiens Clathrin light chain B Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 101100380548 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-2 gene Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000659413 Homo sapiens Tricarboxylate transport protein, mitochondrial Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101100380569 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-5 gene Proteins 0.000 description 1
- 101100436382 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-6 gene Proteins 0.000 description 1
- 101100271302 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-7 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940063137 norditropin Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000003889 oxyphil cell of parathyroid gland Anatomy 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of high-glycosylation human growth hormone's fusion protein.Fusion protein described in human growth hormone's fusion protein of the present invention contains human growth hormone (hGH), flexible peptide linker (L), human chorion gonadotrophic hormone beta subunit carboxyl terminal rigidity peptide (CTP) and human normal immunoglobulin's Fc fragment successively from N end to C end.The invention also discloses a kind of efficient method preparing this kind of fusion protein.The fusion protein that the present invention builds has more excellent internal drug effect than restructuring hGH, the circulating half-life in vivo of prolongation, and administration frequency is substantially reduced and bioavailability improves;Its production process is simpler, efficiently simultaneously.
Description
Technical field
The present invention relates to fusion protein field, more particularly it relates to an high-glycosylation human growth hormone is merged
Albumen and its production and use.
Background technology
Human growth hormone (human growth hormone, hGH) is secreted by anterior pituitary oxyphil cell
Planting proteohormone, be made up of 191 aminoacid, its physiological function is chiefly to facilitate substance metabolism and growth promoter.HGH passes through
Somatomedin or insulin like growth factor mediation, in cartilaginous tissue, increase bone length, thus reach to promote human body
Linear growth.Recent years, the more function of hGH was found, including promoting skeletal muscle and Myocyte growth, promotion albumen
The effects such as matter synthesis, regulation function of immune system and enhancing immune defence ability.The larger scale clinical of hGH is applied also from initial
The prevention of the children short stature of growth hormone deficiency and treatment, be extended to the necks such as burn, acute pancreatitis, old people's slow down aging
Territory, its clinical indication is also in constantly extension.
Child and adult, in the case of growth hormone deficiency, can be treated by external source supplementation with growth hormones.
The internal removing half-life of natural hGH is about 0.3 hour, the internal removing half-life of current business-like recombinant human somatropin
It is about 2-3 hour, liver, kidney removing will soon being passed through after injection, so needing subcutaneous administrations every day, carrying to patient
Come a lot of painful.Additionally, long term injections recombinant human somatropin produces antibody in a few patients body and affects the treatment.Therefore,
A kind of technology is needed to extend the activity that can also keep higher while hGH circulating half-life in vivo.Build recombinant long-acting, height
The human growth hormone of activity, the immunogenicity reduced and higher bioavailability becomes the primary mesh of drug development of future generation
Mark.
For stable protein, prevent the scavenging action of enzymolysis and kidney, such as Polyethylene Glycol (PEG) can be used to modify
(Sada et al., J.Ferment Bioeng 71:137-139,1991), glycosylation modified transformation (U.S. Patent number US 7,
217,689) and with other protein the method for (WO 93/15199) is merged to promote body absorption, to prevent from being degraded and kidney
Remove.The albumen that PEG modifies is prevented from hydrolysis, will not cause serious side effects, but PEG belongs to non-with target protein coupling
Specific covalent combines, and this random coupling interaction between target protein and its receptor that hinders in various degree causes
Its activity in vivo reduces.Increase glycosylation and can increase the molecular weight of target protein, filter critical line especially for being in kidney
Protein (~30KD), glycosylation can reduce the protein sensitivity to protease hydrolysis.Korean Patent Publication No
KR10-2013-0029713 discloses by introducing at least one sudden change addition N-glycosyl on α-1 antitrypsin, attempts increasing
The method adding Half-life in vivo.The glycosylation modified of protein has two classes, including O-sugar chain and N-sugar chain.But, sugar chain attached
And adding to cause physiologically active protein matter to inactivate, and can additionally adhere to the selection face in the site of the physiologically active protein matter of sugar chain
The narrowest, therefore introduce the glycosylation engineering of extra glycosylation site to protein and be not also widely used.
The another kind of method improving albumen pharmacokinetics and internal stability is to be connected by the gene of physiologically active protein
On the expressing gene of an albumen with high stability, by gene recombination technology to produce fusion protein.Fc merges egg
Be in vain utilize the technology such as genetic engineering certain is had biologic activity functional protein molecule (soluble ligand, receptor or its
He needs to extend the bioactive substance of half-life) with Fc segment composition and the novel recombinant protein that produces.Such fusion protein
Not only remain the biologic activity of functional protein molecule, moreover it is possible to extend the half-life of fusion protein and improve its stability, Fc
The interchain disulfide bond of fragment is conducive to fusion molecule to form dimer, thus strengthens ligand binding capacity and improve biological activity;
The introducing of Fc fragment also advantageously improves fusion molecule expression in mammalian cell.Therefore manufacture and contain and people
The fusion protein that the Fc region of IgG albumen is connected, it will help extend the circulating half-life of medicine and/or increase the biological alive of it
Property.Patent CN102875683 discloses the Fc fusion protein of a kind of long-acting recombinant human growth hormone, becomes at hGH and human IgG Fc
Body adds one section of flexible peptide linker to reduce space steric effect, it is contemplated that target is to make its extended serum half lives, biological
Activity increases, thus improves pharmacokinetics and drug effect.But, owing to the avtive spot of hGH is mainly at C end, C-terminal merges
Other albumen leverage activity and the function of hGH, CN102875683 patent shows the hGH-L-vFc's of dimerization
Molar specific activity is 1.2nM, and it is the most not ideal enough that its activity compares restructuring hGH.Studying discovery according to the present invention, simple prolongation is soft
Property peptide linker, increase Fc Yu hGH C end space length can not solve problem, need other method solve fusion part pair
A difficult problem for hGH activity influence.It is contemplated that find new fusion method, improve further fusion protein serum half-life and
Activity in vivo.
CTP is the small peptide of one section of β from human chorionic gonadotropin (hCG)-subunit carboxyl terminal.Four kinds and reproduction
Relevant peptide hormone, follicle stimulating hormone (FSH), lutropin (LH), thyrotropin (TSH) and chorionic gonadotrophin
Hormone (hCG) contains identical α-subunit and the most special β-subunit.Compared with other three kinds of hormones, hCG Half-life in vivo
Being obviously prolonged, this is mainly derived from (the Fares FA et al.Proc Natl of distinctive carboxyl terminal peptide (CTP) on its β-subunit
Acad Sci USA.89:4304–4308,1992).CTP contains 37 amino acid residues, and it has 4 O-glycosylation sites,
Terminal is sialic acid residues.CTP can increase the level of glycosylation of protein, improves the activity of target protein, the most electronegative,
The most sialylated CTP can resist the kidney scavenging action to it, thus extends the albumen half-life in vivo.The U.S. is special
Profit 13,195,931 discloses a kind of method by connecting chorionic-gonadotropin hormone carboxyl terminal peptide (CTP) on hGH, makes
Growth hormone circulating half-life only extends about 6 times, but and the size of not mentioned several hGH/CTP chimeric protein external activity;
The display of internal drug effect is merged the chimeric protein of 1 or 2 CTP molecule and is relatively recombinated the weak effect of hGH, only CTP-hGH-CTP-CTP
This chimeric protein drug effect being fitted together to 3 CTP molecules is slightly above recombinated hGH.The present inventor creatively will have multiple O-
The CTP polypeptide in glycosyl site, as a part for connection peptides, is used for connecting hGH and Fc fragment rather than sending out as merging part
Wave effect, the native glycosylation sites having because of it, the half-life of fusion protein can not only be made to extend further, bioavailability
Improve, be also greatly reduced the fusion part Fc steric effect to hGH so that it is maintain higher biologic activity simultaneously.
Comprehensive above content, has had many protein fusion methods to be constructed to develop long acting protein class medicine,
But the most still there is no activity and half-life the most gratifying long-acting hGH preparation.Therefore, this area is long in the urgent need to exploitation
Effect, high activity, purification step are simple, be easy to the long-acting hGH of industrialized production.
Summary of the invention
The present invention is to solve the restructuring problem that hGH serum half-life is short and biological activity is poor, design and be prepared for one
The long-acting hGH fusion protein of high-glycosylation.The present inventor, through in-depth study for a long time, devises the peptide linker of uniqueness first
That reduces between fusion molecule is sterically hindered, the C end of hGH be connected the fusion protein formed with Fc, middle with flexible peptide and just
Property peptide connect.Unexpectedly, the external activity of the hGH-L-vFc that this fusion protein was developed than former the present inventor improves about
1 times (seeing, China Patent No. CN102875683).Additionally, also achieve unforeseeable technique effect, the most described fusion egg
White bioavailability is also greatly improved.
In a first aspect of the present invention, it is provided that a kind of restructuring hGH fusion protein, described fusion protein depends on to C end from N end
Secondary containing human growth hormone (hGH), flexible peptide linker (L), human chorion gonadotrophic hormone beta-subunit carboxyl terminal rigidity peptide
And human normal immunoglobulin's Fc fragment (CTP);Wherein, Fc fragment preferred human IgG Fc variant (being expressed as vFc).
Wherein, the preferred non-immunogenic of described flexible peptide linker, and between hGH and Fc, produce enough distances,
Steric effect each other is made to be down to minimum.It is preferred that use the flexible peptide containing following 2 or multiple Amino acid profile to connect
Head: Gly (G), Ser (S), Ala (A) and Thr (T).Preferably, described flexible peptide linker comprises G and S residue.The length of connection peptides
Spend extremely important to the activity of fusion protein.For the purpose of the present invention, it is preferable that the structure of described flexible peptide linker aminoacid composition
Formula is (GS)a(GGS)b(GGGS)c(GGGGS)d, wherein a, b, c and d are greater than or equal to the integer of 0, and a+b+c+d >=1.
In some embodiments of the present invention, described peptide linker is selected from following sequence:
(a) L1:GSGGGSGGGGSGGGGS;
(b) L2:GSGGGGSGGGGSGGGGSGGGGSGGGGS;
(c) L3:GSGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS;
(d) L4:GGGGSGGGGSGGGGSGGGGS.
Wherein, described human chorion gonadotrophic hormone beta-subunit carboxyl terminal peptide rigidity peptide (CTP) selects free human chorionic
Full length sequence that gonadotrophin beta subunit carboxyl terminal the 113rd to 145 amino acids is formed or its fragment are (hereinafter referred to as
CTP), specifically, described CTP rigidity peptide comprises SEQ ID NO:1 or the sequence of its truncate.
Preferably, described CTP rigidity peptide comprises at least 2 glycosylation sites;Such as, a preferred embodiment of the present invention
In, described CTP comprises 2 glycosylation sites, and exemplarily, described CTP comprises 10 aminoacid of SEQ ID NO:1N end, i.e.
SSSS*KAPPPS* (* represents glycosylation site);Or described CTP comprises 14 aminoacid, i.e. S* of SEQ ID NO:1C end
RLPGPS*DTPILPQ;And for example, in another embodiment, described CTP comprises 3 glycosylation sites, exemplarily, described CTP bag
16 aminoacid, i.e. SSSS*KAPPPS*LPSPS*R containing SEQ ID NO:1N end;For another example, in other embodiments, described
CTP comprises 4 glycosylation sites, and exemplarily, described CTP sequence comprises 28,29,30,31,32 or 33 aminoacid and starts
In the 113rd, 114,115,116,117 or 118 of human chorion gonadotrophic hormone beta subunit, terminate at the 145th.Specifically,
Described CTP comprises 28 aminoacid, i.e. SSSS*KAPPPS*LPSPS*RLPGPS*DTPILPQ of SEQ ID NO:1N end.Every kind
Probability all represents the standalone embodiment of the present invention.
In further embodiments, the CTP rigid element that the present invention provides is same with natural CTP aminoacid sequence at least 70%
Source;In further embodiments, CTP rigid element and natural CTP aminoacid sequence at least 80% homology that the present invention provides;?
In other embodiments, the CTP rigid element that the present invention provides and natural CTP aminoacid sequence at least 90% homology;At another
In a little embodiments, the CTP rigid element that the present invention provides and natural CTP aminoacid sequence at least 95% homology.
Preferably, in embodiments of the invention, described CTP rigidity peptide preferably comprises following sequence units:
(i)CTP1: SSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(ii)CTP2: PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(iii)CTP3: SSSSKAPPPS;
(iv)CTP4: SRLPGPSDTPILPQ.
Fusion protein of the present invention can also comprise the above-mentioned CTP rigidity peptide sequence unit of 2 or more than 2, such as this
In one embodiment of invention, described CTP comprises 2 CTP3Unit: SSSSKAPPPSSSSSKAPPPS (CTP3-CTP3, or represent
For (CTP3)2)。
Wherein, extend half-life part and preferably be selected from immunoglobulin IgG, IgM, IgA Fc fragment;More preferably from human IgG1,
The Fc fragment of IgG2, IgG3 or IgG4 and variant thereof;Further, described human IgG Fc variant comprises and is positioned at wild type human IgG
At least one in Fc is amino acid modified, and variant have reduction effector function (ADCC and/or CDC effect) and/or with
The binding affinity of neonatal receptor FcRn strengthens.Further, human IgG Fc variant is selected from lower group:
(a)vFcγ1: containing Leu234Val, Leu235Ala and Pro331Ser sudden change human IgG1 hinge region, CH2 and
CH3 region (aminoacid sequence as shown in SEQ ID NO:4);
(b)vFcγ2-1: human IgG2 hinge region containing Pro331Ser sudden change, CH2 and CH3 region is (such as SEQ ID NO:5
Shown aminoacid sequence);
(c)vFcγ2-2: containing Pro331Ser, Thr250Gln and Met428Leu sudden change human IgG2 hinge region, CH2 and
CH3 region (aminoacid sequence as shown in SEQ ID NO:6);
(d)vFcγ4: containing Ser228Pro and Leu235Ala sudden change human IgG 4 hinge region, CH2 and CH3 region (as
Aminoacid sequence shown in SEQ ID NO:7).
More preferably, the aminoacid sequence of described hGH-L-CTP-vFc fusion protein is as shown in SEQ ID NO:2.
In a second aspect of the present invention, it is provided that recombinate described in a kind of coding first aspect present invention hGH-L-CTP-vFc
The DNA molecular of fusion protein, it is preferable that described DNA sequence has the nucleotide sequence shown in SEQ ID NO:3.
According to the third aspect of the invention we, it is provided that a kind of carrier, this carrier comprises the DNA sequence described in second aspect present invention
Row.
According to the fourth aspect of the invention, it is provided that a kind of host cell, this host cell comprises third aspect present invention institute
State carrier, or transfect above-mentioned carrier.
In the detailed description of the invention of the present invention, host cell is the derived cell strain DXB-11 of CHO.
Preferably, described host cell in every 24 hours, produces thin more than 30 μ g/ million in its growth medium
The restructuring hGH-L-CTP-vFc fusion protein as described in the first aspect of the invention of born of the same parents.
In a fifth aspect of the present invention, it is provided that one prepares restructuring hGH-L-CTP-vFc described in first aspect present invention
The method of fusion protein, described method includes:
A the DNA of encoding fusion protein is introduced Chinese hamster ovary celI by (), generate CHO derived cell system;
In (b) screening step (a) in every 24 hours periods, express more than 30 μ g/106(million) high yield of individual cell is thin
Born of the same parents' strain;
C cell strain that () incubation step (b) screens, expressed fusion protein;
D fermentation liquid that () results step (c) obtains, purified fusion protein.
In a sixth aspect of the present invention, the invention provides a kind of pharmaceutical composition, described pharmaceutical composition includes pharmacy
Upper acceptable carrier, excipient or diluent, and the described hGH-L-CTP-vFc fusion protein of effective dose.
Another further aspect, the invention provides described hGH-L-CTP-vFc fusion protein for treating because of endogenous growth
The dysplasia that hormone secretion deficiency causes, and the build that Turner syndrome causes is short and small, chronic renal failure,
Prader-Willi syndrome or the disease such as idiopathic build is short and small.
To sum up, the fusion part human IgG Fc that fusion protein structure of the present invention has the following characteristics that 1, fusion protein uses
Variant is non-cracking performance, reduces the effector function being combined and trigger with Fc γ Rs and Clq;2, fusion prepared by the present invention
No matter albumen is respectively provided with good stability during fermentation, purge process and storage;3, by L-CTP connect hGH with
Fc variant, CTP rigidity peptide can not only extend its Half-life in vivo further;Obstruct by multiple glycosylation side chains simultaneously is made
With, increase the space length between fusion molecule, promote each autofolding of hGH and Fc section to form correct three-dimensional conformation and be independent of each other
Respective biological activity, compared with hGH-L-vFc, the biological activity of hGH-L-CTP-vFc increases substantially;4, fusion protein tool
There is the immunogenicity of reduction so that it is the risk reduction that induction neutralizing antibody produces;5, compared with hGH-L-vFc, hGH-L-CTP-
VFc has the bioavailability of raising, and blood concentration fluctuation is little, and safety improves, and improves toleration;There is the internal of prolongation follow
The ring half-life, it is possible to decrease frequency of injection, improve patient compliance;6, compared with restructuring hGH, hGH-L-CTP-vFc purification step
Simply, purification efficiency is high.
In should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the present invention and having in below (eg embodiment)
Can be combined with each other between each technical characteristic that body describes, thus constitute new or preferred technical scheme.As space is limited, exist
This tires out the most one by one states.
Detailed Description Of The Invention:
IgG Fc variant
Non-cracking performance Fc variant
Fc element derives from the constant region fc fragment of immunoglobulin IgG, and it rises in the immune defence of eliminating pathogen
Important function.The effector function of the IgG of Fc mediation plays by two kinds of mechanism: (1) and cell-surface Fc receptors (Fc γ Rs)
In conjunction with, phagocytosis or splitting action or killing cell digest cause of disease by antibody dependent cellular cytotoxicity (ADCC) approach
Body, or (2) be combined with the C1q of the first complement component C1, causes CDC (CDC) approach, thus cracks disease
Substance.For the treatment being applied to people, the hGH being incorporated on target cell surface when hGH-L-CTP-vFc fusion protein is subject to
During body, the Fc region of fusion protein does not the most have ill effect subfunction, from without dissolving or removing these target cell.
Therefore, the Fc region of hGH-Fc must be non-deliquescent, to being incorporated into Fc γ Rs and Clq thus trigger effect subfunction side
Face, Fc region is preferably inactive.In four kinds of human IgG hypotypes, IgG1 and IgG3 can effectively combine Fc γ Rs, IgG4 and Fc
The binding affinity of γ Rs is relatively low, and the combination of IgG2 with Fc γ Rs is so low that to be difficult to measure, so human IgG2 is almost without ADCC
Effect.Additionally, human IgG1 and IgG3 can also effectively combine C1q and activating complement cascade reaction.Human IgG2 combines relative with C1q
Weak, and IgG4 is not combined (Jefferis R etc., Immunol Rev, 1998,163:59-76) with C1q, so human IgG2 CDC effect
Should be the most weak.Obviously, a kind of natural IgG hypotype is not had to be especially suitable for producing hGH fusion protein.In order to not had effector merit
The non-cracking performance Fc of energy, most effectual way is to complement, receptor binding domains sudden change transformation, regulation Fc and associated receptor in Fc fragment
Binding affinity, reduce or eliminate ADCC and CDC effect, only retaining the long circulating half-life characteristics of Fc, and do not produce cell
Toxicity.The comprised mutational site of more non-cracking performance Fc variant may refer to Shields RL etc., J Biol Chem, 2001,
276 (9): 6591-604 or Chinese invention patent CN 201280031137.2.
Pharmacokinetically improved Fc variant
The plasma half-time of IgG depends on the combination of it and FcRn, typically combines when pH 6.0, at pH 7.4 (blood plasma
PH) dissociate time.By the research to both binding sites, the site that transformation IgG is combined with FcRn, it is allowed to when pH 6.0 tie
Conjunction ability increases.The sudden change having turned out some residues for combining people's Fc γ domain important for FcRn can increase serum half
Decline the phase.Especially, in people Fc γ 1, when three residues are substituted by other 19 conventional amino acid, some point mutation display increases
FcRn binding affinity (Hinton etc., J Biol Chem, 279 (8): 6213-6216,2004).Hinton etc. find
2 mutants of T250Q and M428L make the combination with FcRn increase by 3 and 7 times respectively.2 sites of simultaneous mutation, then combine increase
28 times.In rhesus monkeys, M428L or T250QM428L mutant display plasma half-time increases by 2 times of (Paul R.Hinton
Deng, J Immunol, 2006,176:346-356).Additionally, there is research that the Fc section of five kinds of humanized antibodies is carried out T250Q/
M428L sudden change not only improves the interaction of Fc Yu FcRn, and in internal pharmacokinetic trial subsequently, finds with skin
Hemostasis is administered, and Fc mutant antibodies pharmacokinetic parameter compared with wild-type antibodies improves, and internal exposed amount increases, clearance rate
Reduce, subcutaneous bioavailability be improved (.MAbs.Taylor&Francis such as Datta-Mannan A, 2012,4 (2):
267-273.)。
Carboxyl terminal peptide (CTP)
CTP is the small peptide of one section of β from human chorionic gonadotropin (hCG)-subunit carboxyl terminal.Four kinds and reproduction
Relevant peptide hormone follicle stimulating hormone (FSH), lutropin (LH), thyrotropin (TSH) and chorionic gonadotrophin
Hormone (hCG) contains identical α-subunit and the most special β-subunit.Compared with other three kinds of hormones, hCG Half-life in vivo
Being obviously prolonged, this is mainly derived from distinctive carboxyl terminal peptide (CTP) (Fares FA etc., Proc Natl on its β-subunit
Acad Sci USA,1992,89:4304-4308).CTP contains 37 amino acid residues, and it has 4 O-glycosylation sites,
Terminal is sialic acid residues.Electronegative, the most sialylated CTP can resist the kidney scavenging action to it, thus extends
The albumen half-life in vivo.Thus, inventor creatively increases at least one after the flexible peptide linker of suitable length
CTP polypeptide so that the half-life of fusion protein extends further, bioavailability improves.
Additionally, by increasing CTP peptide between hGH and Fc variant, be equivalent to add one section of peptide that is rigidly connected.This is on the one hand
Ensure that the hGH that N-end merges does not interferes with the binding site of Fc variant and FcRn, thus affect the half-life;Additionally Fc
Protein A binding site is critically important for purification step in preparation technology, connects CTP and ensures that the hGH of N-end fusion also will not
" cover " binding site of it and protein A.On the other hand, the interpolation of CTP also makes the Fc fragment of about 25KD size will not
The correct folding of the hGH that interference N-end merges, so that the decline of its biologic activity/function or forfeiture.There is multiple glycosyl
Side chain rigidity CTP polypeptide, relative to the random coil of this kind of flexible peptide linker of (GGGGS) n, it can form stable standing
Body conformation, this " obstruct " effect promotes hGH and Fc section independently to fold the correct three-dimensional conformation of formation and be independent of each other respective
Biological activity.
Fusion protein and production method thereof
Fusion protein of the present invention is generally prepared by biosynthetic method.According to nucleotide sequence of the present invention, this
Technical field personnel can prepare the code nucleic acid of the present invention easily with various known methods.These methods such as but not limited to:
PCR, DNA synthetic etc., concrete method can be found in J. Pehanorm Brooker, " Molecular Cloning: A Laboratory guide ".As the present invention
A kind of embodiment, the method that can be carried out Overlap extension PCR by salvage nucleotide sequence again builds the present invention's
Nucleic acid sequence encoding.
Present invention also offers a kind of expression vector, the sequence of the fusion protein comprising code book invention and operating therewith
Property be connected expression regulation sequence.Described " being operatively connected " or " being operably coupled to " refers to such a situation, the most linearly
Some part of DNA sequence can regulate or control the activity of same linear DNA molecule other parts.Such as, if promoter
Control transcribing of sequence, then it is operably coupled to coded sequence exactly.
Expression vector can use commercially available such as but not limited to: pcDNA3, pIRES, pDR, it is thin that pUC18 etc. can be used for eucaryon
The carrier of born of the same parents' system expression.Those skilled in the art can select suitable expression vector according to host cell.
According to the restriction enzyme mapping of known unloaded expression vector, those skilled in the art can be conventionally by restricted
Enzyme is sheared and splicing, and the coded sequence of the fusion protein of the present invention is inserted suitable restriction site, prepares the weight of the present invention
Group expression vector.
Present invention also offers the host cell expressing fusion protein of the present invention, wherein contain the fusion protein of the present invention
Coded sequence.Described host cell preferably eukaryotic cell, such as but not limited to CHO, COS cell, 293 cells, RSF is thin
Born of the same parents etc..As the optimal way of the present invention, described cell is Chinese hamster ovary celI, and it can express the fusion protein of the present invention well,
Combination activity can be obtained good, the fusion protein having good stability.
The present invention also provides for a kind of method that recombinant DNA prepares fusion protein of the present invention, and its step includes:
1) nucleotide sequence (such as SEQ ID NO:3 sequence) of encoding fusion protein is provided;
2) by 1) nucleotide sequence be inserted into suitable expression vector, it is thus achieved that recombinant expression carrier;
3) by 2) recombinant expression carrier import suitable host cell;
4) transformed host cell is cultivated under conditions suitable for the expression;
5) supernatant is collected, and purified fusion protein product.
Described coded sequence importing host cell can be used the multiple known technology of this area, such as but not limited to: phosphorus
Acid calcium deposit, protoplast fusion, liposome transfection, electroporation, microinjection, reverse transcription method, phage transduction method, alkali metal from
Sub-method.
Cultivation and expression about host cell can be found in Olander RM Dev Biol Stand 1996;86:338.
Clear liquid can be collected by the cell in centrifugal segregation suspension and residue.Can be identified by agarose gel electrophoresis technology.
Can be substantially uniform character by the above-mentioned fusion protein purification prepared, such as on SDS-PAGE electrophoresis in
Single band.Such as, when recombiant protein is secreting, expressing, the ultrafilter membrane of commercialization can be used to separate described albumen, example
Such as Products such as Millipore, Pellicon, first will express supernatant and concentrate.Concentrated solution can use the method for gel chromatography
The most in addition purification, or use the method purification of ion-exchange chromatography.Such as anion-exchange chromatography (DEAE etc.) or sun from
Sub-displacement chromatography.Gel-type vehicle can be the substrate that agarose, glucosan, polyamide etc. are usually used in protein purification.Q-or SP-group
It it is ideal ion-exchange group.Finally, can also be used with hydroxylapatite adsorption chromatography, metal chelate chromatography, hydrophobic mutually
The method polishing purification further to above-mentioned purified product such as effect chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC).Above-mentioned institute
There is purification step to may utilize different combinations, finally make purity of protein reach substantially uniform.
The fusion to expressing of the available affinity column containing the specific antibody of described fusion protein, receptor or part
Albumen is purified.According to the characteristic of the affinity column used, available conventional method, such as high-salt buffer, change pH etc.
Method elution of bound amalgamation polypeptide on affinity column.Selectively, the aminoterminal of described fusion protein or c-terminus are also
One or more polypeptide fragments can be contained, as protein tag.Any suitable label may be used to the present invention.Such as, institute
The label stated can be FLAG, HA, HAl, c-Myc, 6-His or 8-His etc..These labels can be used for carrying out pure to fusion protein
Change.
Pharmaceutical composition
Present invention also offers a kind of pharmaceutical composition, it contains effective dose (such as 0.000001-90wt%;Preferably
0.1-50wt%;More preferably, 5-40wt%) the fusion protein of the present invention, and pharmaceutically acceptable carrier.Generally, may be used
The fusion protein of the present invention of effective dose is formulated in nontoxic, in inert and pharmaceutically acceptable aqueous carrier medium, its
Middle pH ordinarily be about 5-8, it is preferred that pH is about 6-8.Term " effective dose " or " effective dose " refer to can be to people and/or animal
Amount that is that produce function or activity and that can be accepted by people and/or animal.The composition of " pharmaceutically acceptable " applies to people
And/or mammal and without excessive bad side reaction (such as toxicity, stimulation and allergy), i.e. there is rational benefit/wind
The material of danger ratio.Term " pharmaceutically acceptable carrier " refers to the carrier for Therapeutic Administration, including various excipient and dilute
Release agent.
Pharmaceutically acceptable carrier includes (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and
A combination thereof.Generally pharmaceutical preparation should match with administering mode, and the pharmaceutical composition of the present invention can be to be made into injection form, example
As being prepared by conventional method with normal saline or the aqueous solution containing glucose and other adjuvant.Described drug regimen
Thing the most aseptically manufactures.The dosage of active component is therapeutically effective amount.The pharmaceutical preparation of the present invention may also be fabricated which slow
Release formulation.
The effective dose of fusion protein of the present invention can be with the pattern being administered and the order of severity etc. of disease to be treated
And change.The preferably selection of effective dose can be determined according to various factors by those of ordinary skill in the art and (such as passes through
Clinical trial).Described factor includes but not limited to: the pharmacokinetic parameter of described fusion protein such as biological utilisation
Degree, metabolism, half-life etc.;The order of severity of the disease that patient is to be treated, the body weight of patient, the immune state of patient, administration
Approach etc..Generally, when the present invention fusion protein every day with about 0.00001mg-50mg/kg the weight of animals (preferably
0.0001mg-10mg/kg the weight of animals) dosage give, gratifying effect can be obtained.Such as, compeling by treatment situation
Highly necessary ask, the most separate dosage can be given every day, or dosage is reduced pari passu.
Accompanying drawing explanation
Fig. 1, show the fusion protein of Spe I-EcoR I fragment in pAPG-3 expression vector nucleotide sequence and
The aminoacid sequence derived.Peptide linker position in maturation protein marks with lower stroke of dotted line.In Fc region, the nucleotide of runic
Mark with corresponding amino acid variant underscore.
Fig. 2, show hGH fusion protein stimulate Nb2-11 cell proliferation ability.
Fig. 3, show the Drug-time curve of hGH fusion protein.
Fig. 4, show hGH fusion protein be administered after the growth curve of each group.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention
Rather than restriction the scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, generally according to conventional strip
Part such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory
Press, 1989) condition described in, or according to the condition proposed by manufacturer.
Embodiment 1, the expression plasmid of structure coding hGH fusion protein
Coding hGH leader peptide and the gene order of ripe hGH and different length flexible peptide linker, different length CTP are firm
Property peptide and the gene order of different IgG Fc variants be all the Chinese hamster ovary celI preference codon of artificial optimization, through chemical synthesis process
Obtain.For the ease of the specific site by purpose fragment inserting expressioning carrier, it is respectively arranged with a limit at synthesized fragment 5 ' and 3 ' end
Property enzyme inscribe site processed, respectively SpeI and EcoRI.Fusion gene SpeI after sequence verification and EcoRI enzyme action, then insert
Enter to PCDNA3.1 as template and between the corresponding restriction enzyme site of improved expression plasmid PXY1A1, obtain track fusion
Plasmid pAPG.PXY1A1 plasmid is including but not limited to following important expression components and parts: 1) human cytomegalic inclusion disease virus early promoter and
Enhancer needed for mammalian cell height heterogenous expression;2) Double Selection label, has kalamycin resistance in antibacterial,
Mammalian cell has G418 resistance;3) mouse dihydrofolate reductase (DHFR) gene expression frame, when host cell is
During DHFR gene defection type, methotrexate (MTX) can coamplification fusion gene and DHFR gene (see United States Patent (USP) US 4,
399,216)。
As shown in table 1, the present invention constructs a series of hGH-Fc fusion protein, and they have the flexible peptide of different length and connect
Head, CTP composition and also position are different, and IgG Fc variant (vFc) the element composition of several different subtype.Wherein APG-3
The aminoacid sequence of nucleotide sequence and translation is as shown in Figure 1.
Table 1, several hGH fusion protein composition built
Embodiment 2, transient expression difference fusion protein and active determination in vitro
The a series of expression plasmids obtained in embodiment 1, use DNAFect LT reagent in the shaking flask of 30ml
(ATGCell) transfection 3 × 107Chinese hamster ovary celI, the cell through transfecting grows 5 days in serum free growth medium, according to correspondence
ELISA method measures the fusion protein concentration in supernatant, and measures the work of its extracorporeal biology by the method described in embodiment 5
Property.ELISA result shows that several plasmid transient expression amount under this condition is more or less the same, but their activity but demonstrates
Bigger difference (table 2).Wherein, the molar specific activity of APG-1 is defined as 100% by us.The activity of APG-2 is APG-1's
80.9%, show only can not be effectively improved the activity of fusion protein by extending peptide linker, space steric effect the most each other is also
Can not weaken along with the extension of peptide linker.Even, long peptide linker not only can not improve the activity of fusion protein, on the contrary can
Make protein misfolding, with inactive multimeric forms secretion.It is presumed that reason, long flexible peptide linker makes fusion egg
White flexibility ratio is higher so that it is can be freely rotatable, this may make the stereochemical structure of hGH closer to Fc district, and at the two it
Between add CTP, on the one hand quite add one end rigidity peptide linker, make away from each other, it is often more important that CTP contains multiple glycosyl sides
Chain, relative to the random coil form of flexible peptide linker, CTP can form fixing space conformation, it is possible to effectively separates
The difference in functionality district of fusion protein, this is more beneficial for two parts and is independently folded into correct three-dimensional conformation, maintains higher work
Property.The correctness of this supposition is demonstrated by the expression activitiy of APG-1, APG-2 and APG-3.And CTP is placed in Fc C end
The activity of APG-4 only CTP is placed in the 61.3% of the APG-3 of Fc N end, and the activity of APG-4 is similar to the APG-1 without CTP.
And specific activity APG-4 of APG-3 is high, the activity of APG-5, APG-6 and APG-7 to be also far above other fusion protein.More than tie
Really, it was demonstrated that CTP is the most crucial to the activity of fusion protein, and CTP is placed in the N end of Fc and is more beneficial for improving the work of fusion protein
Property.
Table 2, the external activity EC of various fusion protein of transient expression50Value compares
The expression in transfectional cell series of embodiment 3, fusion protein
The expression plasmid of restructuring is transfected into mammalian host cell line, to express hGH-L-CTP-vFc fusion protein.
In order to stablize high-caliber expression, preferred host cell system be DHFR deficient CHO-cell (see United States Patent (USP) US 4,
818,679).A kind of preferably transfection method is electroporation, it is possible to use other method, turns including calcium phosphate cosedimentation, fat
Dye and Protoplast fusion.In electroporation, with being set to 300V electric field and the Gene Pulser of 1050 μ Fd electric capacity
Electroporator (Bio-Rad Laboratories, Hercules, CA), places 5 × 10 in cuvette7Individual cell,
It is subsequently added the 50 μ linearizing plasmids of g BspCI and carries out electroporation.In transfection two days later, culture medium is made into containing 0.6mg/mL
The growth medium of G418.After transfecting about 2 weeks, the transfectant to G418 medicine with resistance can grow up to macroscopic cell mass
Fall.By the elisa assay method of anti-human igg Fc, screen the transfectant selecting medication to have resistance.Also can be with anti-hGH's
ELISA carries out the quantitative analysis of fusion protein expression.By Method of Limited Dilution 96 well culture plate, sub-clone produces high level Fc and melts
The hole of hop protein.
In order to realize the expression of fusion protein higher level, preferably carry out coamplification with the DHFR gene by MTX Drug inhibition.
In the growth medium containing progressive concentration MTX, with the antigen-4 fusion protein gene of DHFR gene coamplification transfection.Use Method of Limited Dilution
The transfectant that can grow in up to 6 μMs of MTX culture medium of sub-clone.Measure secretion rate the cell line of sub-clone is entered
The analysis of one step.Secretion rate horizontal exceeding about 30 (being preferably about 50) μ g/106The cell line of (i.e. million) individual cell/24 hour
Adapt to use the suspension culture of serum free growth medium.Use conditioned medium purified fusion protein the most again.
Embodiment 4, fusion protein purification with qualitative
With 1N NaOH, the conditioned medium containing fusion protein is titrated to pH 7~8, then with the nitric acid of 0.45 micron
Cellulose filter filters.Filtrate is loaded onto on the Protein A post that phosphate buffer saline (PBS) balances.To be fused
Protein binding, after Protein A post, discards the component of outflow.This post is washed, until the OD value at 280nm is less than with PBS
0.01.Then with the fusion protein of the citrate buffer solution elution of bound that 0.1M pH is 3.75.The eluent 1M of 0.4 volume
K2HPO4Neutralize, merge the component containing purifying protein, and use PBS.Then with the nitrocellulose filter of 0.22 micron
Filter, and be stored in 4 DEG C.Under non reducing conditions, SDS-PAGE protein product identified and analyze.Use BSA conduct
Standard, by BCA protein analysis quantitatively this fusion protein.
Embodiment 5, the Bioactivity analysis of fusion protein
Nb2-11 cell proliferation is utilized to detect the In vitro biological activity of restructuring hGH-L-CTP-Fc fusion protein.
Mouse lymphoma cell Nb2-11 (the U.S. is normally cultivated by the Fischer's culture medium containing 10% hyclone
ATCC cell bank).Using serum-free medium, 1000ng/ml initiates 3 times of gradient dilution fusion protein, it is thus achieved that 8 variable concentrations
Sample, every hole 100 μ l, add to 96 orifice plates, culture medium is negative control.Take the cell being in logarithmic (log) phase trophophase, by nothing
Once, adjust density is every milliliter 3 × 10 to blood serum medium washed cell6Individual cell, every hole 100 μ l joins above-mentioned 96 orifice plates
In.At 37 DEG C, 5%CO2Cultivating 48 hours in incubator, (Cell Counting Kit, purchased from Shanghai to use CCK-8 test kit
Yi Sheng bio tech ltd) detection cell proliferative conditions.The absorbance at 450nm is measured, by OD reading by microplate reader
Mapping relative to the concentration of fusion protein, gained dose-effect curve calculates the biological activity of fusion protein.
Fig. 2 shows that hGH fusion protein stimulates the ability of Nb2 cell proliferation.Table 3 is that the half of different fusion protein is effective
Concentration value (half maximal effective concentration, EC50).Due to the aminoacid of growth hormone C end and its
Function is closely related, and Fc is directly connected with the C section of hGH can affect its biological activity.After adding connection peptides in hGH Yu Fc, hGH
The activity raising of fusion protein.It can be seen from the results that the activity of APG-3 is compared with APG-1, activity improves will by about one time.This
Being likely due to CTP mono-aspect and play the function of self, on the other hand as the peptide that is rigidly connected between Fc and hGH, CTP is with soft
Property peptide coupling, this structure makes fusion protein be folded into more favourable three dimensional structure, it is ensured that the biological activity of hGH.
Table 3, the EC of hGH fusion protein50Value
Embodiment 6, the pharmacokinetics of fusion protein measure
Male SPF level SD rat (purchased from Shanghai Bi Kai laboratory animal company limited), after raising in advance one week, often group selects body weight
About 294g rat 3, single 0.176mg/kg gives intravenous injection APG-1 and APG-3 fusion protein, investigates blood medicine dense
Degree and the Changing Pattern of time.Matched group and administration group the most upon administration 0,0.5,1,2,3,4,5,8,10,24,48,72h warp
Eye socket is taken a blood sample, and blood 5000r/min after room temperature places 30min is centrifuged 10min, isolates serum ,-20 DEG C of preservations.With for
ELISA method special for hGH measures hGH content in each time point serum.By software PKSOLVER, calculate each group of main medicine generation
Kinetic parameter.Each group pharmacokinetic parameter result such as table 4.
Table 4, the pharmacokinetic parameter of hGH fusion protein
Being found out by result, the Half-life in vivo of APG-3 and APG-1 fusion protein is respectively 2.6 and 2.4 hours, the half-life
Basically identical, this point can also be found out from MRT parameter, the two in vivo residence time also close to.When the medicine of Fig. 3
Find on curve that the blood drug level of APG-3 is always high than APG-1, thus it is speculated that the change being probably APG-3 structure result in its medicine generation
Dynamic (dynamical) character there occurs change;The CLTB of APG-3 only has the half of APG-1, shows the internal removing phase of APG-3
To slowly, and the apparent volume of distribution of APG-3 is the twice of APG-1, illustrate APG-1 enter internal after be distributed to tissue rapidly
In, result in its blood drug level less than APG-3.Apparent volume of distribution and CLTB there occurs change, and the two acts on jointly
Result be that the blood drug level of APG-3 is higher than APG-1, the internal exposed amount (AUC) of medicine is the highest simultaneously.
APG-1 is after the sudden change in Fc site, thus it is speculated that it compares exposed amount increase, clearance rate reduction than unmutated.
APG-3 adds the structure of CTP on the basis of APG-1, reduces clearance rate further and increases AUC, reaching above-mentioned two
After individual purpose, the most further reduce apparent volume of distribution owing to introducing CTP rigid structure so that it is be distributed more in the tissue
Few, medical content in blood is higher, causes internal exposed amount higher, so the structural grouping advantage of APG-3 is not only embodied in excellent
Medicine more is in parameter, and its drug effect may be also superior to APG-1, because APG-3 blood drug level after transformation is higher, and meaning
Free medicine in vivo more than APG-1, so the drug effect of APG-3 is better than APG-1, bioavailability is higher, it is contemplated that
Its clinical administration dosage will also decrease.As can be seen here, APG-3 shows excellence in terms of biologic activity and pharmacokinetics
Performance.
Embodiment 7, the Biological acdtivity in vivo of fusion protein measure
Choosing 4 week old SPF level male SD rats, body weight 60-80g, by National Institute for Food and Drugs Control's laboratory animal
Center provides.
Testing first 2 weeks clean conditions menisectomy Hypophysectomies, removing hypophysis Post operation 2 weeks is convalescent period, selects big before being administered
Mus body weight change, less than the qualified healthy animal of operation consent body weight ± 10%, goes hypophysis rat to be divided into 6 groups by body weight is uniformly random,
5/group.The positive reference tested as this with fugitive rhGH (trade name norditropin, Novo Nordisk A/S produces)
Medicine 1 (Y1), than 3IU/mg alive;Using PEG-rhGH (Changchun Jinsai Medicine Co., Ltd) as positive with reference to medicine 2 (Y2), than
Live 6IU/mg;APG-3 is basic, normal, high, and dosage setting is respectively 5mg/kg/14d, 15mg/kg/14d and 45mg/kg/14d.According to
Molecular size range and molal quantity, the middle dosage 15mg/kg/14d of APG-3 is suitable with reference to medicine Y1 and Y2 with positive.Administering mode is
Cervical region subcutaneous injection, various dose APG-3 fusion protein and Y2, every Mus was administered once in the 1st day and the 8th day;Y1 is administered every day
1 time, continuous 14 days.
After administration, every rat is weighed every day, the 15th day with carbon dioxide suffocate execution whole rats, weigh.Every animal
I-th day (di) body weight (bwi) i.e. 1st day (d1) body weight (bw front with administration1) the body weight that i.e. increases of difference (if desired, experiment terminates
After can perform an autopsy on sb., cut sella region, macroscopy with or without hypophysis remain, reject have hypophysis remaining animal).Body weight increases meter
Calculation formula: Δ bw=bwi–bw1, wherein: Δ bw is weight gain;bw1For d1 body weight before being administered;bwiFor being administered latter i-th day body
Weight.Measurement data is with mean standard deviationRepresent, the results are shown in Table 5.Fig. 4 is the growth curve of each group after showing administration.
Rat body weight change before and after the administration of table 5, hGH fusion protein (N=7)
From the results, it was seen that compared with model group, the 8th day each administration group Δ bw all dramatically increases upon administration, but respectively
Between administration group, Δ bw value difference is different the most notable;And the 15th day upon administration, APG-3 has highly significant to the body weight growth of rat
Facilitation, it is rhGH (Y1) and PEG-rhGH (Y2) that high dose APG-3 induction Hypophysectomized rats body weight increases (Δ bw value)
About 1.5 times of group;And the body weight increase of middle dosage APG-3 induction is slightly better than Y1, basically identical with Y2.It was found that APG-3 is high
Rat body weight is increased after being administered at the 2nd time by dosage group, shows more significant facilitation compared with PEG-rhGH group, and
Being administered in one week after for 1st time, the Δ bw value of two groups does not the most have significant difference.Deduce from this diversity interpretation of result
APG-3 compares PEG-rhGH should have the longer activity in vivo half-life, and therefore after repeat administration, this body accumulation effect makes
Obtain the ascendant trend of growth curve after APG-3 group is administered at the 2nd time more precipitous.
The all documents mentioned in the present invention are incorporated as reference the most in this application, just as each document by individually
It is incorporated as with reference to like that.In addition, it is to be understood that after the above-mentioned teachings having read the present invention, those skilled in the art can
To make various changes or modifications the present invention, these equivalent form of values fall within the model that the application appended claims is limited equally
Enclose.
Claims (13)
1. recombinant human somatropin's fusion protein, it is characterised in that described fusion protein contains people from N end successively to C end
Growth hormone, flexible peptide linker, the carboxyl terminal rigidity peptide of at least one human chorion gonadotrophic hormone beta subunit and people's immunity ball
Albumen Fc fragment;Wherein Fc fragment preferred human IgG Fc variant;It is highly preferred that described human IgG Fc variant comprises is positioned at wild type
At least one in human IgG Fc is amino acid modified, and variant has effector function and/or and the neonatal receptor of reduction
The binding affinity of FcRn strengthens.
2. fusion protein as claimed in claim 1, it is characterised in that described flexible peptide linker contains two or more selected from sweet
The aminoacid of propylhomoserin, serine, alanine and threonine, it is preferred that the general structure of flexible peptide linker aminoacid composition is
(GS) a (GGS) b (GGGS) c (GGGGS) d, wherein a, b, c and d are greater than or equal to the integer of 0, and a+b+c+d >=1,
It is highly preferred that the aminoacid of described flexible peptide linker is selected from following sequence:
(a)GSGGGSGGGGSGGGGS;
(b)GSGGGGSGGGGSGGGGSGGGGSGGGGS;
(c)GSGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS;
(d)GGGGSGGGGSGGGGSGGGGS。
3. fusion protein as claimed in claim 1, it is characterised in that the carboxyl of described human chorion gonadotrophic hormone beta subunit
End rigidity peptide comprises SEQ ID NO:1 or the sequence of its truncate, and the sequence of wherein said truncate comprises at least 2 glycosylation positions
Point,
Preferably, the carboxyl terminal rigidity peptide of described human chorion gonadotrophic hormone beta subunit is selected from following sequence units:
(i)SSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(ii)PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(iii)SSSSKAPPPS;
(iv)SRLPGPSDTPILPQ。
4. fusion protein as claimed in claim 1, it is characterised in that the carboxyl of described human chorion gonadotrophic hormone beta subunit
Terminal peptide rigid element at least has 70%, 80%, 90% with the CTP aminoacid sequence in fusion protein described in claim 3
Or the homogeneity of 95%.
5. fusion protein as claimed in claim 1, it is characterised in that described fusion protein comprises 1,2,3,4 or 5 human chorionics
The carboxyl terminal peptide rigid element of film gonadotrophin beta subunit.
6. fusion protein as claimed in claim 1, it is characterised in that described human IgG Fc is selected from lower group:
A () contains the human IgG1 hinge region of Leu234Val, Leu235Ala and Pro331Ser sudden change, CH2 and CH3 region;
B () contains the human IgG2 hinge region of Pro331Ser sudden change, CH2 and CH3 region;
C () contains the human IgG2 hinge region of Pro331Ser, Thr250Gln and Met428Leu sudden change, CH2 and CH3 region;
D () contains human IgG 4 hinge region of Ser228Pro and Leu235Ala sudden change, CH2 and CH3 region.
7. fusion protein as claimed in claim 1, it is characterised in that the aminoacid sequence of described fusion protein such as SEQ ID
Shown in NO:2.
8. the DNA molecular of the fusion protein encoded described in any one of claim 1-7, it is preferred that described DNA molecular tool
There is the nucleotide sequence shown in SEQ ID NO:3.
9. a carrier, it is characterised in that comprise DNA molecular as claimed in claim 8.
10. a host cell, it is characterised in that comprise carrier as claimed in claim 9, or transfected claim 9
Described carrier.
Prepare the method for recombination fusion protein as described in claim 1-7 for 11. 1 kinds, it is characterised in that comprise the steps:
A the DNA of encoding fusion protein is introduced Chinese hamster ovary celI by (), generate CHO derived cell system;
In (b) screening step (a) in every 24 hours periods, express the high yield cell more than 30 μ g/106 (million) individual cells
Strain;
C cell strain that () incubation step (b) screens, expressed fusion protein;
D fermentation liquid that () results step (c) obtains, purified fusion protein;
Preferably, the CHO derived cell system in step (a) is DXB-11.
12. 1 kinds of pharmaceutical compositions, it is characterised in that described compositions contains with good grounds claim 1-7 any one claim
Described fusion protein and pharmaceutically acceptable carrier.
13. fusion protein as described in claim 1-7 are for preparing the medicine for the treatment of endogenous growth hormone hyposecretion
Purposes.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610694877.4A CN106256835A (en) | 2016-08-19 | 2016-08-19 | High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes |
CN201710202564.7A CN107286248B (en) | 2016-08-19 | 2017-03-30 | High-glycosylation human growth hormone (HGH) fusion protein and preparation method thereof and purposes |
PCT/CN2017/079873 WO2018032787A1 (en) | 2016-08-19 | 2017-04-10 | Highly glycosylated human growth hormone fusion protein, and manufacturing method and application of same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610694877.4A CN106256835A (en) | 2016-08-19 | 2016-08-19 | High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106256835A true CN106256835A (en) | 2016-12-28 |
Family
ID=57713904
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610694877.4A Pending CN106256835A (en) | 2016-08-19 | 2016-08-19 | High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes |
CN201710202564.7A Active CN107286248B (en) | 2016-08-19 | 2017-03-30 | High-glycosylation human growth hormone (HGH) fusion protein and preparation method thereof and purposes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710202564.7A Active CN107286248B (en) | 2016-08-19 | 2017-03-30 | High-glycosylation human growth hormone (HGH) fusion protein and preparation method thereof and purposes |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN106256835A (en) |
WO (1) | WO2018032787A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018032786A1 (en) * | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof |
WO2020050626A1 (en) * | 2018-09-05 | 2020-03-12 | 주식회사 엘지화학 | Fusion polypeptide comprising polypeptide region that can be o-glycosylated |
CN110950964A (en) * | 2018-09-26 | 2020-04-03 | 安源医药科技(上海)有限公司 | Mutant single-chain human coagulation factor VIII fusion protein and preparation method and application thereof |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021005155A (en) | 2018-11-01 | 2021-09-30 | Shandong New Time Pharmaceutical Co Ltd | Bispecific antibody and use thereof. |
CN109942717A (en) * | 2019-04-24 | 2019-06-28 | 上海延立药业有限公司 | A kind of long-acting recombinant human follicle-stimulating hormone (FSH) and its preparation method and application |
CN113264985A (en) * | 2021-02-26 | 2021-08-17 | 长沙市信励致和科技有限责任公司 | Human chorionic gonadotropin peptide aptamer and preparation method and application thereof |
CN114010765A (en) * | 2021-08-30 | 2022-02-08 | 上海延立药业有限公司 | Long-acting human growth hormone |
CN114213523B (en) * | 2021-11-15 | 2024-07-09 | 广州源博医药科技有限公司 | Hyperglycosylation modification sequence for recombinant protein, recombinant porcine follicle stimulating hormone and application thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103501A (en) * | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
CN102875683B (en) * | 2011-07-11 | 2014-06-11 | 旭华(上海)生物研发中心有限公司 | Fc fusion protein of long-acting recombinant human growth hormone |
BR112014015156A2 (en) * | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | ctp-based insulin analogues, their methods of production and use in the treatment of hyperglycemia, as well as nucleic acid and host cell sequences |
KR102041412B1 (en) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | Derivatives of Immunglobulin Fc fragment |
US9915665B2 (en) * | 2012-12-28 | 2018-03-13 | Abbvie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
CN105229035A (en) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | Growth hormone compound |
MX2016003705A (en) * | 2013-09-27 | 2016-05-16 | Hanmi Pharm Ind Co Ltd | Sustained type human growth hormone preparation. |
CN104693270B (en) * | 2013-12-10 | 2018-10-16 | 清华大学 | A kind of connection peptide for fusion protein |
CN107759694B (en) * | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | Bispecific antibody, preparation method and application thereof |
CN106279437B (en) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes |
CN106117370B (en) * | 2016-08-19 | 2017-05-17 | 安源医药科技(上海)有限公司 | Hyperglycosylated Extendin-4, fusion protein of analogue thereof, and preparation method and application of fusion protein |
CN106279436B (en) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Human blood coagulation factor VII fusion protein of activation and preparation method thereof and purposes |
-
2016
- 2016-08-19 CN CN201610694877.4A patent/CN106256835A/en active Pending
-
2017
- 2017-03-30 CN CN201710202564.7A patent/CN107286248B/en active Active
- 2017-04-10 WO PCT/CN2017/079873 patent/WO2018032787A1/en active Application Filing
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
WO2018032785A1 (en) * | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof |
CN108137708A (en) * | 2016-08-19 | 2018-06-08 | 安源医药科技(上海)有限公司 | Human factor IX fusion protein and preparation method thereof and purposes |
WO2018032786A1 (en) * | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof |
US11833212B2 (en) | 2016-08-19 | 2023-12-05 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
US11472863B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof |
WO2020050626A1 (en) * | 2018-09-05 | 2020-03-12 | 주식회사 엘지화학 | Fusion polypeptide comprising polypeptide region that can be o-glycosylated |
CN112654637A (en) * | 2018-09-05 | 2021-04-13 | 株式会社Lg化学 | Fusion polypeptide comprising polypeptide region which can be O-glycosylated |
JP7562209B2 (en) | 2018-09-05 | 2024-10-07 | エルジー・ケム・リミテッド | Fusion Polypeptides Containing O-Glycosylatable Polypeptide Regions |
JP2021535746A (en) * | 2018-09-05 | 2021-12-23 | エルジー・ケム・リミテッド | A fusion polypeptide containing an O-glycosylizable polypeptide region |
CN110950964A (en) * | 2018-09-26 | 2020-04-03 | 安源医药科技(上海)有限公司 | Mutant single-chain human coagulation factor VIII fusion protein and preparation method and application thereof |
CN113105562B (en) * | 2018-09-26 | 2023-12-01 | 安源医药科技(上海)有限公司 | Application of mutant single-chain human coagulation factor VIII in preparation of fusion protein |
CN113105562A (en) * | 2018-09-26 | 2021-07-13 | 安源医药科技(上海)有限公司 | Application of mutant single-chain human coagulation factor VIII in preparation of fusion protein |
CN110950964B (en) * | 2018-09-26 | 2021-06-18 | 安源医药科技(上海)有限公司 | Mutant single-chain human coagulation factor VIII fusion protein and preparation method and application thereof |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Also Published As
Publication number | Publication date |
---|---|
CN107286248A (en) | 2017-10-24 |
WO2018032787A1 (en) | 2018-02-22 |
CN107286248B (en) | 2018-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106256835A (en) | High-glycosylation human growth hormone's fusion protein and preparation method thereof and purposes | |
CN108137708B (en) | Human factor IX fusion protein and preparation method thereof and purposes | |
CN104804096B (en) | Long-acting polypeptides and its production and application process | |
CN104918632B (en) | Treatment diabetes or sugar is fat sick includes the composition of Oxyntomodulin analogs | |
US9808534B2 (en) | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides | |
CN109851674B (en) | Preparation and purification method of recombinant human serum albumin/growth hormone fusion protein for treating children's dwarf syndrome | |
CN110028587A (en) | For adjusting the Synergistic type bifunctional protein of blood glucose and lipid | |
CN1341121A (en) | Expression and export of anti-obesity proteins as Fc fusion proteins | |
RU2624129C2 (en) | Method for producing physiologically active polypeptide complex | |
WO2011060583A1 (en) | Nonnatural collagen-like protein and use thereof | |
CN103539860B (en) | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) | |
CN103897064B (en) | Long-acting recombinant human chorionic gonadotrophin fusion | |
CN103539861B (en) | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) | |
CN104066845A (en) | Soluble IGF receptor Fc fusion proteins and uses thereof | |
CN104271604A (en) | An improved process for preparation of physiologically active polypeptide complex | |
CN106117370A (en) | The fusion protein of high-glycosylation Exendin 4 and the like, Preparation Method And The Use | |
JP2022088521A (en) | Long-acting polypeptides and methods of producing and administering the same | |
CN103641896A (en) | Use of gelatin-like unit | |
CN106432511A (en) | GLP-1 analogue-Fc fusion protein and preparation method and application thereof | |
TW201514207A (en) | An improved process for high yield preparation of physiologically active polypeptide complex | |
CN106279430A (en) | Exendin-4 analog fusion and its production and use | |
CN108794634A (en) | The long-acting human growth hormone (HGH) fusion protein and its preparation and use of recombination | |
CN103804498B (en) | Long-acting restructuring chorionic gonadotrophin and application thereof | |
CN106029105A (en) | A process for preparing a composition of pegylated proteins | |
JP2018508465A (en) | Methods for producing long acting CTP-modified growth hormone polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161228 |
|
WD01 | Invention patent application deemed withdrawn after publication |